Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: Results of an open, randomized, multicenter clinical trial

Clinical Infectious Diseases

Volumn 43, Issue 1, 2006, Pages 79-89

  Miro, Jose M ^a,g   Lopez, Juan C ^d   Podzamczer, Daniel ^a   Peña, Jose M ^e   Alberdi, Juan C ^f   Martínez, Esteban ^a   Domingo, Pere ^b   Cosin, Jaime ^d   Claramonte, Xavier ^a   Arribas, Jose R ^e   Santín, Miguel ^a   Ribera, Esteban ^c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; COTRIMOXAZOLE; DIDANOSINE; INDINAVIR; LAMIVUDINE; MALOPRIM; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; ENCEPHALITIS; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RNA ANALYSIS; TOXOPLASMA GONDII; TOXOPLASMIC ENCEPHALITIS; TOXOPLASMOSIS; TREATMENT RESPONSE;

ADULT; ANIMALS; ANTI-HIV AGENTS; ANTIBIOTIC PROPHYLAXIS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HUMANS; IMMUNE SYSTEM; MALE; RNA, VIRAL; TOXOPLASMA; TOXOPLASMOSIS;

EID: 33745291928     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/504872     Document Type: Article

References (39)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
2. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352:1725-30.
3. Forrest DM, Seminari E, Hogg RS, et al. The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs. Clin Infect Dis 1998; 27:1379-85.
4. Lopez Bernaldo de Quiros JC, Miro JM, Pena JM, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med 2001; 344:159-67.
5. Ledergerber B, Mocroft A, Reiss P, et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med 2001; 344:168-74.
6. Aberg JA, Williams PL, Liu T, et al. A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex. AIDS Clinical Trial Group 393 Study Team. J Infect Dis 2003; 187:1046-52.
7. Tural C, Romeu J, Sirera G, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis 1998; 177:1080-3.
8. Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med 1999; 340:1301-6.
9. Jubault V, Pacanowski J, Rabian C, Viard JP. Interruption of prophylaxis for major opportunistic infections in HIV-infected patients receiving triple combination antiretroviral therapy. Ann Med Interne (Paris) 2000; 151:163-8.
10. Furrer H, Opravil M, Bernasconi E, Telenti A, Egger M. Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. Swiss HIV Cohort Study. Lancet 2000; 355:2217-8.
11. Mussini C, Pezzotti P, Govoni A, et al. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type 1-infected patients: the changes in opportunistic prophylaxis study. J Infect Dis 2000; 181:1635-42.
12. Kirk O, Lundgren JD, Pedersen C, Nielsen H, Gerstoft J. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy? AIDS 1999; 13:1647-51.
13. Soriano V, Dona C, Rodriguez-Rosado R, Barreiro P, Gonzalez-Lahoz J. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2000; 14:383-6.
14. Zeller V, Truffot C, Agher R, et al. Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium complex infection and toxoplasmic encephalitis. Clin Infect Dis 2002; 34:662-7.
15. Kirk O, Reiss P, Uberti-Foppa C, et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002; 137:239-50.
16. Benson CA, Kaplan JE, Masur H, et al. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep 2004; 53(RR-15):1-112.
17. US Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. USPHS/IDSA Prevention of Opportunistic Infections Working Group. MMWR Morb Mortal Wkly Rep 1997; 46(RR-12):1-46.
18. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41(RR-17):1-19.
19. Leport C, Chene G, Morlat P, et al. Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial Group. J Infect Dis 1996; 173:91-7.
20. Miró JM, García F, Cruceta A, et al. Trimethoprim- sulfamethoxazole versus dapsone plus pyrimethamine as primary prophylaxis of CNS toxoplasmosis and P. carinii pneumonia in HIV-infected patients [abstract 647]. In: Program and abstracts of the 6th European Conference on Clinical Aspects and Treatment of HIV-Infection (Hamburg, Germany). 1997.
21. Pedrol E, Gonzalez-Clemente IM, Gatell IM, et al. Central nervous system toxoplasmosis in AIDS patients: efficacy of an intermittent maintenance therapy. AIDS 1990; 4:511-7.
22. Podzamczer D, Miro JM, Bolao F, et al. Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Spanish Toxoplasmosis Study Group. Ann Intern Med 1995; 123:175-80.
23. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351:1682-6.
24. + T cell count. J Acquir Immune Defic Syndr 2004; 36:702-13.
25. Podzamczer D, Salazar A, Jimenez I, et al. Intermittent trimethoprimsulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med 1995; 122:755-61.
26. Colin JA, McMeeking A, Cohen W, Jacobs J, Holzman RS. Evaluation of the policy of empiric treatment of suspected Taxoplasma encephalitis in patients with the acquired immunodeficiency syndrome. Am J Med 1989; 86:521-7.
27. Katlama C, De Wit S, O'Doherty U, Van Glabekc M, Clumeck N. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 1996; 22:268-75.
28. Podzamczer D, Miro IM, Ferrer E, et al. Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study Group. Eur J Clin Microbiol Infect Dis 2000; 19:89-95.
29. Plana M, Ferrer E, Martínez C, et al. Immune restoration in HIV-positive, antiretroviral naive patients after 1 year of zidovudine/ lamivudine plus nelfinavir or nevirapine. Antivir Ther 2004; 9:197-204.
30. Pulido F, Arribas JR, Miró JM, et al. Clinical, virologic, and immunologic response to cfavirenz- or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients with advanced HIV infection (EfaVIP 2 Study). J Acquir Immune Defic Syndr 2004; 35:343-50.
31. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999; 282:2220-6.
32. + T lymphocyte immune function in long-term survivors of AIDS-related CMV end-organ disease who are receiving potent antiretroviral therapy. J Infect Dis 2001; 183:1399-404.
33. Fournier S, Rabian C, Alberti C, et al. Immune recovery under highly active antiretroviral therapy is associated with restoration of lymphocyte proliferation and interferon-gamma production in the presence of Taxoplasma gondii antigens. J Infect Dis 2001; 183:1586-91.
34. Miró JM, Lejeune M, Claramonte X, et al. Timing of reconstitution of Toxoplasma gondii-specific T-cell responses in AIDS patients with acute toxoplasmic encephalitis after starting HAART: a prospective multicenter longitudinal study [abstract 796]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). 2003.
35. Ghosn J, Paris L, Ajzenberg D, et al. Atypical toxoplasmic manifestation after discontinuation of maintenance therapy in a human immunodeficiency virus type 1-infected patient with immune recovery. Clin Infect Dis 2003; 37:e112-4.
36. Kaplan IE, Hanson DL, Jones JL, Dworkin MS. Adult and adolescent spectrum of HIV disease project investigators: viral load as an independent risk factor for opportunistic infections in HIV-infected adults and adolescents. AIDS 2001; 15:1831-6.
37. Swindells S, Evans S, Zackin R, et al. Predictive value of HIV-1 viral load on risk for opportunistic infection. J Acquir Immune Defic Syndr 2002; 30:154-8.
38. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999; 13:1933-42.
39. Tenorio AR, Smith KY, Kuritzkes DR, et al. HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course. J Acquir Immune Defic Syndr 2003; 34:491-6.